Candidate biomarker verification: Critical examination of a serum protein pattern for human colorectal cancer

Proteomics - Clinical Applications

Volumn 6, Issue 3-4, 2012, Pages 182-189

  Albrethsen, Jakob ^a   Rikke Bogebo ^a   Møller, Christian H ^a   Olsen, Jesper A ^b   Raskov, Hans H ^c   Gammeltoft, Steen ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c Raskov's Clinic   (Denmark)

Author keywords

Biomarker; Colorectal cancer; Serum; Translational research

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; FIBRINOGEN; HEMOGLOBIN A; PLASMA PROTEIN; PREALBUMIN; TUMOR MARKER;

ARTICLE; BENIGN TUMOR; CANCER CLASSIFICATION; COLORECTAL CANCER; CONTROLLED STUDY; EXPERIMENTAL DESIGN; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PROTEINS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; PROTEOLYSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; TUMOR MARKERS, BIOLOGICAL;

EID: 84860325202     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100095     Document Type: Article

References (27)

1. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
2. Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., et al. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93, 1054-1061.
3. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
4. Ransohoff, D. F., Proteomics research to discover markers: what can we learn from Netflix? Clin. Chem. 2010, 56, 172-176.
5. Albrethsen, J., The first decade of MALDI protein profiling: a lesson in translational biomarker research. J. Proteomics 2011, 74, 765-773.
6. Mischak, H., Allmaier, G., Apweiler, R., Attwood, T., et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci. Transl. Med. 2010, 2, 46ps42.
7. Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5(17), 4589-4596.
8. Malik, G., Ward, M. D., Gupta, S. K., Trosset, M. W., et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 2005, 11, 1073-1085.
9. Li, J., Orlandi, R., White, C. N., Rosenzweig, J., et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 2005, 51, 2229-2235.
10. Vlahou, A., Schellhammer, P. F., Mendrinos, S., Patel, K., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 2001, 158, 1491-1502.
11. Ward, D. G., Cheng, Y., N'Kontchou, G., Thar, T. T., et al. Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br. J. Cancer 2006, 94, 287-292.
12. Koomen, J. M., Shih, L. N., Coombes, K. R., Li, D., et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 2005, 11, 1110-1118.
13. Chen, Y. D., Zheng, S., Yu, J. K., Hu, X., Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 2004, 10, 8380-8385.
14. Ward, D. G., Suggett, N., Cheng, Y., Wei, W., et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 2006, 94, 1898-1905.
15. Yu, J. K., Chen, Y. D., Zheng, S., An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol. 2004, 10, 3127-3131.
16. Liu, X. P., Shen, J., Li, Z. F., Yan, L., et al. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest. 2006, 24, 747-753.
17. Engwegen, J. Y., Helgason, H. H., Cats, A., Harris, N., et al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 2006, 12, 1536-1544.
18. Schoen, R. E., The case for population-based screening for colorectal cancer. Nat. Rev. Cancer 2002, 2, 65-70.
19. Sturgeon, C., Practice guidelines for tumor marker use in the clinic. Clin. Chem. 2002, 48, 1151-1159.
20. Ransohoff, D. F., Lessons from controversy: ovarian cancer screening and serum proteomics. J. Natl. Cancer Inst. 2005, 97, 315-319.
21. Albrethsen, J., Bøgebo, R., Olsen, J., Raskov, H., et al. Preanalytical and analytical variation of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry of human serum. Clin. Chem. Lab. Med. 2006, 44, 1243-1252.
22. Albrethsen, J., Evaluation of Type 1 Diabetes serum cohort by SELDIprotein profiling. Proteomics Clin. Appl. 2009, 3, 383-393.
23. Albrethsen, J., Bøgebo, R., Gammeltoft, S., Olsen, J., et al. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005, 5, 8.
24. Blom, N., Gammeltoft, S., Brunak, S., Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J. Mol. Biol. 1999, 294, 1351-1362.
25. Tolson, J., Bogumil, R., Brunst, E., Beck, H., et al. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab. Invest. 2004, 84, 845-856.
26. Chechlinska, M., Kowalewska, M., Nowak, R., Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat. Rev. Cancer 2010, 10, 2-3.
27. Fung, E. T., Yip, T. T., Lomas, L., Wang, Z., et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 2005, 115, 783-789.